Liposome imaging agents in personalized medicine

Advanced Drug Delivery Reviews

Volumn 64, Issue 13, 2012, Pages 1417-1435

  Petersen, Anncatrine L ^a   Hansen, Anders E ^b   Gabizon, Alberto ^c   Andresen, Thomas L ^a  

^a TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^b Mental Health Services CPH   (Denmark)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Cancer; Diagnostics; Nanomedicine; Nanoparticles; Nanotheranostics; Nuclear imaging; PET; Radionuclides; SPECT; Theranostics

Indexed keywords

CANCER; NANOTHERANOSTICS; NUCLEAR IMAGING; SPECT; THERANOSTICS;

DIAGNOSIS; LIPOSOMES; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; PATIENT TREATMENT; PLASMA DIAGNOSTICS; POLYETHYLENE TEREPHTHALATES; RADIOISOTOPES; TISSUE;

DISEASES;

8 QUINOLINOL INDIUM IN 111; CISPLATIN; DEFEROXAMINE; DOXORUBICIN; FLUCICLATIDE F 18; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GEFITINIB; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; LIPOSOME; NITROGEN 13; PENTETATE INDIUM IN 111; TAMOXIFEN; TRASTUZUMAB; WATER O 15;

ADVANCED CANCER; BREAST TUMOR; CANCER DIAGNOSIS; CANCER PROGNOSIS; CARCINOMA; COLORECTAL CANCER; DOSIMETRY; DRUG ACCUMULATION; DRUG DISTRIBUTION; ENCAPSULATION; GLIOBLASTOMA; HALF LIFE TIME; HUMAN; IMAGE QUALITY; ISOTOPE LABELING; KAPOSI SARCOMA; LUNG NON SMALL CELL CANCER; MEMBRANE LABELING; MEMBRANE PERMEABILITY; MOLECULAR IMAGING; NONHUMAN; PARTICLE SIZE; PERSONALIZED MEDICINE; PLASMA CLEARANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY CONTROL; RADIATION SAFETY; RADIOISOTOPE DECAY; REMOTE LOADING; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SQUAMOUS CELL CARCINOMA; SURFACE CHELATION; TUMOR XENOGRAFT;

ANIMALS; DIAGNOSTIC IMAGING; HUMANS; INDIVIDUALIZED MEDICINE; LIPOSOMES; NEOPLASMS; RADIOPHARMACEUTICALS;

EID: 84867640019     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2012.09.003     Document Type: Review

References (198)

1. Gambhir S. Molecular imaging of cancer with positron emission tomography. Nat. Rev. Cancer 2002, 2:683-693.
2. Phelps M.E., Hoffman E.J., Mullani N.A., Terpogossian M.M. Application of annihilation coincidence detection to transaxial reconstruction tomography. J. Nucl. Med. 1975, 16:210-224.
3. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin. Cancer Res. 2010, 16:978-985.
4. Miele E., Spinelli G.P., Tomao F., Zullo A., De Marinis F., Pasciuti G., Rossi L., Zoratto F., Tomao S. Positron Emission Tomography (PET) radiotracers in oncology - utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC). J. Exp. Clin. Cancer Res. 2008, 27:52.
5. Schoder H., Larson S.M. Positron emission tomography for prostate, bladder, and renal cancer. Semin. Nucl. Med. 2004, 34:274-292.
6. Jensen G.M., Bunch T.H. Conventional liposome performance and evaluation: lessons from the development of vescan. J. Liposome Res. 2007, 17:121-137.
7. Proffitt R.T., Williams L.E., Presant C.A., Tin G.W., Uliana J.A., Gamble R.C., Baldeschwieler J.D. Tumor-imaging potential of liposomes loaded with In-111-NTA - biodistribution in mice. J. Nucl. Med. 1983, 24:45-51.
8. Khalifa A., Dodds D., Rampling R., Paterson J., Murray T. Liposomal distribution in malignant glioma: possibilities for therapy. Nucl. Med. Commun. 1997, 18:17-23.
9. Kubo A., Nakamura K., Sammiya T., Katayama M., Hashimoto T., Hashimoto S., Kobayashi H., Teramoto T. Indium-111-labeled liposomes - dosimetry and tumor-detection in patients with cancer. Eur. J. Nucl. Med. 1993, 20:107-113.
10. Presant C.A., Proffitt R.T., Turner A.F., Williams L.E., Winsor D., Werner J.L., Kennedy P., Wiseman C., Gala K., Mckenna R.J., Smith J.D., Bouzaglou S.A., Callahan R.A., Baldeschwieler J., Crossley R.J. Successful imaging of human cancer with indium-111-labeled phospholipid-vesicles. Cancer 1988, 62:905-911.
11. Presant C., Blayney D., Proffitt R., Turner A., Williams L., Nadel H., Kennedy P., Wiseman C., Gala K., Crossley R., Preiss S., Ksionski G., Presant S. Preliminary-report - imaging of Kaposi-sarcoma and lymphoma in aids with indium-111-labeled liposomes. Lancet 1990, 335:1307-1309.
12. Presant C.A., Turner A.F., Proffitt R.T. Potential for improvement in clinical decision-making: tumor imaging with In-111 labeled liposomes results of a phase II-III study. J. Liposome Res. 1994, 4:985-1008.
13. Turner A., Presant C., Proffitt R., Williams L., Winsor D., Werner J. In-111-labeled liposomes - dosimetry and tumor depiction. Radiology 1988, 166:761-765.
14. Awasthi V., Goins B., Klipper R., Phillips W. Dual radiolabeled liposomes: biodistribution studies and localization of focal sites of infection in rats. Nucl. Med. Biol. 1998, 25:155-160.
15. Bao A., Goins B., Klipper R., Negrete G., Mahindaratne M., Phillips W. A novel liposome radiolabeling method using Tc-99m-"SNS/S" complexes: in vitro and in vivo evaluation. J. Pharm. Sci. 2003, 92:1893-1904.
16. Bao A., Goins B., Klipper R., Negrete G., Phillips W. Direct Tc-99m labeling of pegylated liposomal doxorubicin (Doxil) for pharmacokinetic and non-invasive imaging studies. J. Pharmacol. Exp. Ther. 2004, 308:419-425.
17. Suresh M., Cao Y. A simple and efficient method for radiolabeling of preformed liposomes. J. Pharm. Pharm. Sci. 1998, 1:31-37.
18. Beaumier P., Hwang K. An efficient method for loading In-111 into liposomes using acetylacetone. J. Nucl. Med. 1982, 23:810-815.
19. Boerman O., Storm G., Oyen W., Vanbloois L., Vandermeer J., Claessens R., Crommelin D., Corstens F. Sterically stabilized liposomes labeled with In-111 to image focal infection. J. Nucl. Med. 1995, 36:1639-1644.
20. Gabizon A., Huberty J., Straubinger R.M., Price D.C., Papahadjopoulus D. An improved method for in vivo tracing and imaging of liposomes using a gallium 67-deferoxamine complex. J. Liposome Res. 1988, 1:123-135.
21. Hwang K., Merriam J., Beaumier P., Luk K. Encapsulation, with high-efficiency, of radioactive metal-ions in liposomes. Biochim. Biophys. Acta 1982, 716:101-109.
22. Mauk M.R., Gamble R.C. Preparation of lipid vesicles containing high-levels of entrapped radioactive cations. Anal. Biochem. 1979, 94:302-307.
23. Ogihara I., Kojima S., Jay M. Differential uptake of gallium-67-labeled liposomes between tumors and inflammatory lesions in rats. J. Nucl. Med. 1986, 27:1300-1307.
24. Phillips W.T., Rudolph A.S., Goins B., Timmons J.H., Klipper R., Blumhardt R. A simple method for producing a Tc-99m-labeled liposome which is stable in vivo. Nucl. Med. Biol. 1992, 19:539-547.
25. Gambhir S., Herschman H., Cherry S., Barrio J., Satyamurthy N., Toyokuni T., Phelps M., Larson S., Balatoni J., Finn R., Sadelain M., Tjuvajev J., Blasberg R. Imaging transgene expression with radionuclide imaging technologies. Neoplasia 2000, 2:118-138.
26. 18F]FDP). Nucl. Med. Biol. 2007, 34:165-171.
27. Oku N., Tokudome Y., Tsukada H., Kosugi T., Namba Y., Okada S. In vivo trafficking of long-circulating liposomes in tumour-bearing mice determined by positron emission tomography. Biopharm. Drug Dispos. 1996, 17:435-441.
28. Oku N., Yamashita M., Katayama Y., Urakami T., Hatanaka K., Shimizu K., Asai T., Tsukada H., Akai S., Kanazawa H. PET imaging of brain cancer with positron emitter-labeled liposomes. Int. J. Pharm. 2011, 403:170-177.
29. 64Cu loaded liposomes as positron emission tomography imaging agents. Biomaterials 2011, 32:2334-2341.
30. Seo J.W., Mahakian L.M., Kheirolomoom A., Zhang H., Meares C.F., Ferdani R., Anderson C.J., Ferrara K.W. Liposomal Cu-64 labeling method using bifunctional chelators: poly(ethylene glycol) spacer and chelator effects. Bioconjug. Chem. 2010, 21:1206-1215.
31. Seo J.W., Qin S., Mahakian L.M., Watson K.D., Kheirolomoom A., Ferrara K.W. Positron emission tomography imaging of the stability of Cu-64 labeled dipalmitoyl and distearoyl lipids in liposomes. J. Controlled Release 2011, 151:28-34.
32. 64Cu for positron emission tomography (PET) imaging. Bioconjug. Chem. 2008, 19:2577-2584.
33. Goins B., Phillips W. The use of scintigraphic imaging as a tool in the development of liposome formulations. Prog. Lipid Res. 2001, 40:95-123.
34. Phillips W.T., Goins B.A., Bao A. Radioactive liposomes. Rev. Nanomed. Nanobiotechnol. 2009, 1:69-83.
35. Smith S.V. Molecular imaging with copper-64. J. Inorg. Biochem. 2004, 98:1874-1901.
36. Kievit F.M., Zhang M. Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers. Adv. Mater. 2011, 23:H217-H247.
37. Lammers T., Aime S., Hennink W.E., Storm G., Kiessling F. Theranostic nanomedicine. Acc. Chem. Res. 2011, 44:1029-1038.
38. Sumer B., Gao J. Theranostic nanomedicine for cancer. Nanomedicine 2008, 3:137-140.
39. Lammers T., Kiessling F., Hennink W.E., Storm G. Nanotheranostics and image-guided drug delivery: current concepts and future directions. Mol. Pharmaceutics 2010, 7:1899-1912.
40. Goins B. Radiolabeled lipid nanoparticles for diagnostic imaging. Expert Opin. Med. Diagn. 2008, 2:853-873.
41. Sonzogni A. NuDat 2.6, National Nuclear Data Center, Brookhaven National Laboratory (Available at:), (Accessed 04/30, 2012). http://www.nndc.bnl.gov/nudat2/.
42. Vallabhajosula S. Molecular Imaging: Radiopharmaceuticals for PET and SPECT 2009, Springer. 1st ed.
43. Rahmim A., Zaidi H. PET versus SPECT: strengths, limitations and challenges. Nucl. Med. Commun. 2008, 29:193-207.
44. Phelps M.E. PET: Physics, Instrumentation, and Scanners 2006, Springer. 1st ed.
45. Shokeen M., Anderson C.J. Molecular Imaging of Cancer with Copper-64 Radiopharmaceuticals and Positron Emission Tomography (PET). Acc. Chem. Res. 2009, 42:832-841.
46. 60Cu-ATSM in cancer of the uterine cervix. J. Nucl. Med. 2008, 49:1177-1182.
47. Phillips W.T. Delivery of gamma-imaging agents by liposomes. Adv. Drug Deliv. Rev. 1999, 37:13-32.
48. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 2005, 4:145-160.
49. Hnatowich D., Friedman B., Clancy B., Novak M. Labeling of preformed liposomes with Ga-67 and Tc-99m by chelation. J. Nucl. Med. 1981, 22:810-814.
50. Holmberg E., Maruyama K., Litzinger D., Wright S., Davis M., Kabalka G., Kennel S., Huang L. Highly efficient immunoliposomes prepared with a method which is compatible with various lipid compositions. Biochem. Biophys. Res. Commun. 1989, 165:1272-1278.
51. Klibanow A., Maruyama K., Torchilin V., Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990, 268:235-237.
52. Hardy J., Kellaway I., Rogers J., Wilson C. The distribution and fate of I-131-labelled liposomes. J. Pharm. Pharmacol. 1980, 32:309-313.
53. Mougin-Degraef M., Jestin E., Bruel D., Remaud-Le Saec P., Morandeau L., Faivre-Chauvet A., Barbet J. High-activity radio-iodine labeling of conventional and stealth liposomes. J. Liposome Res. 2006, 16:91-102.
54. McDougal I., Dunnick J., McNamee M., Kriss J. Distribution and fate of synthetic lipid vesicles in mouse - combined radionuclide and spin label study. Proc. Natl. Acad. Sci. U. S. A. 1974, 71:3487-3491.
55. 99mTc] technetium-labeled liposomes in normal and tumor-bearing rats. Biochem. Soc. Trans. 1977, 5:290-291.
56. Morgan J.R., Williams K.E., Davies R.L., Leach K., Thomson M., Williams L.A.P. Localization of experimental staphylococcal abscesses by Tc-99m-labeled liposomes. J. Med. Microbiol. 1981, 14:213-217.
57. Laverman P., Dams E., Oyen W., Storm G., Koenders E., Prevost R., van der Meer J., Corstens F., Boerman O. A novel method to label liposomes with Tc-99m by the hydrazino nicotinyl derivative. J. Nucl. Med. 1999, 40:192-197.
58. 99mTc-labeling of lipid vesicles containing the lipophilic chelator PE-DTTA - effect of tin-to-chelate ratio, chelate content and surface polymer on labeling efficiency and biodistribution behavior. Nucl. Med. Biol. 1994, 21:89-96.
59. Ahkong Q., Tilcock C. Attachment of Tc-99m to Lipid Vesicles Containing the Lipophilic Chelate Dipalmitoylphosphatidylethanolamine - DTTA. Nucl. Med. Biol. 1992, 19:831-840.
60. Goto R., Kubo H., Okada S. Liposomes prepared from synthetic amphiphiles.1. Their technetium labeling and stability. Chem. Pharm. Bull. 1989, 37:1351-1354.
61. 18F]-radiolabeling preformed liposomes and determination of liposomal trafficking by positron emission tomography. J. Med. Chem. 2007, 50:6454-6457.
62. 99mTc-labeled liposomes in patients with cancer. Cancer Res. 1984, 44:375-378.
63. Elbayoumi T., Torchilin V. Use of radiolabeled liposomes for tumor imaging. Nanoparticles in biomedical imaging: Fundamental biomedical technologies 2007, 211-236. Springer. 3rd ed. J. Bulte, M. Modo (Eds.).
64. 99mTc-PEG liposomes for the scintigraphic detection of infection and inflammation clinical evaluation. J. Nucl. Med. 2000, 41:622-630.
65. Brouwers A., De Jong D., Dams E., Oyen W., Boerman O., Laverman P., Naber T., Storm G., Corstens F. Tc-99m-PEG-liposomes for the evaluation of colitis in Crohn's disease. J. Drug Target. 2000, 8:225-233.
66. Laverman P., Brouwers A.H., Dams E.T.M., Oyen W.J.G., Storm G., Van Rooijen N., Corstens F.H.M., Boerman O.C. Preclinical and clinical evidence for disappearance of long-circulating characteristics of polyethylene glycol liposomes at low lipid dose. J. Pharmacol. Exp. Ther. 2000, 293:996-1001.
67. Morgan J., Williams L., Howard C. Technetium-labeled liposome imaging for deep-seated infection. Br. J. Radiol. 1985, 58:35-39.
68. Osullivan M., Powell N., French A., Williams K., Morgan J., Williams B. Inflammatory joint disease - A comparison of liposome scanning, bone scanning, and radiography. Ann. Rheum. Dis. 1988, 47:485-491.
69. Williams B., Osullivan M., Saggu G., Williams K., Williams L., Morgan J. Synovial accumulation of technetium labeled liposomes in rheumatoid-arthritis. Ann. Rheum. Dis. 1987, 46:314-318.
70. Gabizon A., Chisin R., Amselem S., Druckmann S., Cohen R., Goren D., Fromer I., Peretz T., Sulkes A., Barenholz Y. Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin. Br. J. Cancer 1991, 64:1125-1132.
71. Harrington K., Mohammadtaghi S., Uster P., Glass D., Peters A., Vile R., Stewart J. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin. Cancer Res. 2001, 7:243-254.
72. Murray J., Kleinerman E., Cunningham J., Tatom J., Andrejcio K., Lepezuniga J., Lamki L., Rosenblum M., Frost H., Gutterman J., Fidler I., Krakoff I. Phase-I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer-patients. J. Clin. Oncol. 1989, 7:1915-1925.
73. Perez Soler R., Lopez Berestein G., Kasi L.P., Cabanillas F., Jahns M., Glenn H., Hersh E.M., Haynie T. Distribution of technetium-99m-labeled multilamellar liposomes in patients with Hodgkins-disease. J. Nucl. Med. 1985, 26:743-749.
74. Richardson V.J., Ryman B.E., Jewkes R.F., Jeyasingh K., Tattersall M.N.H., Newlands E.S., Kaye S.B. Tissue distribution and tumor-localization of 99m-technetium-labeled liposomes in cancer-patients. Br. J. Cancer 1979, 40:35-43.
75. 111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model. Br. J. Cancer 2000, 83:684-688.
76. Andresen T.L., Jensen S., Jorgensen K. Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. Prog. Lipid Res. 2005, 44:68-97.
77. Kaasgaard T., Andresen T.L. Liposomal cancer therapy: exploiting tumor characteristics. Expert Opin. Drug Deliv. 2010, 7:225-243.
78. Ogiharaumeda I., Kojima S. Increased delivery of Ga-67 to tumors using serum-stable liposomes. J. Nucl. Med. 1988, 29:516-523.
79. 18f]fluorodeoxyglucose as positron emission tomography contrast agents in the murine Met-1 tumor model. J. Investig. Med. 2012, 60:234-234.
80. Fugman D., Shirak K., Jackson R., Johnson J. Lipoprotein lipase-A2-catalyzed and phospholipase-A2-catalyzed hydrolysis of phospholipid-vesicles with an encapsulated fluorescent dye - effects of apolipoproteins. Biochim. Biophys. Acta 1984, 795:191-195.
81. Jones M., Nicholas A. The effect of blood-serum on the size and stability of phospholipid liposomes. Biochim. Biophys. Acta 1991, 1065:145-152.
82. Noordam P.C., Killian A., Elferink R.F.M.O., Degier J. Comparative-study on the properties of saturated phosphatidylethanolamine and phosphatidylcholine bilayers - barrier characteristics and susceptibility to phospholipase-A2 degradation. Chem. Phys. Lipids 1982, 31:191-204.
83. Andresen T.L., Thompson D.H., Kaasgaard T. Enzyme-triggered nanomedicine: drug release strategies in cancer therapy (invited review). Mol. Membr. Biol. 2010, 27:353-363.
84. Woodle M.C., Lasic D.D. Sterically stabilized liposomes. Biochim. Biophys. Acta 1992, 1113:171-199.
85. Gregoriadis G. The carrier potential of liposomes in biology and medicine. N. Engl. J. Med. 1976, 295:765-770.
86. Weinstein J.N. Liposomes as drug carriers in cancer-therapy. Cancer Treat. Rep. 1984, 68:127-135.
87. Senior J.H. Fate and behavior of liposomes invivo - a review of controlling factors. Crc Crit. Rev. Ther. Drug Carrier Syst. 1987, 3:123-193.
88. Allen T., Hansen C., Martin F., Redemann C., Yauyoung A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta 1991, 1066:29-36.
89. Papahadjopoulos D., Allen T.M., Gabizon A., Mayhew E., Matthay K., Huang S.K., Lee K.D., Woodle M.C., Lasic D.D., Redemann C., Martin F.J. Sterically stabilized liposomes - improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:11460-11464.
90. 111In-labeled pegylated liposomal vinorelbine in murine colon carcinoma with multimodalities of molecular imaging. J. Nucl. Med. 2009, 50:2073-2081.
91. 99mTc-HMPAO-liposome for improving blood circulation and biodistribution: the effect of the extent of PEGylation. Cancer Biother. Radiopharm. 2005, 20:620-628.
92. Gabizon A. Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. Clin. Cancer Res. 2001, 7:223-225.
93. Allen T.M., Hansen C., Rutledge J. Liposomes with prolonged circulation times - factors affecting uptake by reticuloendothelial and other tissues. Biochim. Biophys. Acta 1989, 981:27-35.
94. Allen T.M., Hansen C. Pharmacokinetics of stealth versus conventional liposomes - effect of dose. Biochim. Biophys. Acta 1991, 1068:133-141.
95. Drummond D., Meyer O., Hong K., Kirpotin D., Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. 1999, 51:691-743.
96. Abra R., Hunt C. Liposome disposition Invivo.3. Dose and vesicle-size effects. Biochim. Biophys. Acta 1981, 666:493-503.
97. Hwang K. Liposome pharmacokinetics. Liposomes: From biophysics to therapeutics 1987, 109-156. Marcel Dekker, Inc., New York. 1st ed. M. Ostro (Ed.).
98. 1-containing liposomes. Biochim. Biophys. Acta 1992, 1104:95-101.
99. Allen T.M., Stuart D. Liposome pharmacokinetics. Classical, sterically stabilized, cationic liposomes and immunoliposomes. Liposomes: Rational design 1998, 63-87. Marcel Dekker, Inc., New York. 1st ed. A. Janoff (Ed.).
100. Allen T.M., Cleland L. Serum-induced leakage of liposome contents. Biochim. Biophys. Acta 1980, 597:418-426.
101. Danhier F., Feron O., Preat V. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Controlled Release 2010, 148:135-146.
102. Elbayoumi T.A., Torchilin V.P. Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: Gamma-imaging studies. Eur. J. Nucl. Med. Mol. Imaging 2006, 33:1196-1205.
103. 111In-labeled polychelating-polymer-containing immunoliposomes. Mol. Pharmaceutics 2006, 3:525-530.
104. Bartlett D.W., Su H., Hildebrandt I.J., Weber W.A., Davis M.E. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:15549-15554.
105. Kirpotin D.B., Drummond D.C., Shao Y., Shalaby M.R., Hong K., Nielsen U.B., Marks J.D., Benz C.C., Park J.W. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006, 66:6732-6740.
106. Oyewumi M.O., Yokel R.A., Jay M., Coakley T., Mumper R.J. Comparison of cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in tumor-bearing mice. J. Controlled Release 2004, 95:613-626.
107. Wang X., Li J., Wang Y., Cho K.J., Kim G., Gjyrezi A., Koenig L., Giannakakou P., Shin H.J.C., Tighiouart M., Nie S., Chen Z., Shin D.M. HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors. Acs Nano 2009, 3:3165-3174.
108. Du S., Pan H., Lu W., Wang J., Wu J., Wang J. Cyclic Arg-Gly-Asp peptide-labeled liposomes for targeting drug therapy of hepatic fibrosis in rats. J. Pharmacol. Exp. Ther. 2007, 322:560-568.
109. Huang G., Zhou Z., Srinivasan R., Penn M.S., Kottke-Marchant K., Marchant R.E., Gupta A.S. Affinity manipulation of surface-conjugated RGD peptide to modulate binding of liposomes to activated platelets. Biomaterials 2008, 29:1676-1685.
110. Schiffelers R., Koning G., ten Hagen T., Fens M., Schraa A., Janssen A., Kok R., Molema G., Storm G. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J. Controlled Release 2003, 91:115-122.
111. Gabizon A., Horowitz A., Goren D., Tzemach D., Shmeeda H., Zalipsky S. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Clin. Cancer Res. 2003, 9:6551-6559.
112. Henriksen G., Schoultz B., Michaelsen T., Bruland O., Larsen R. Sterically stabilized liposomes as a carrier for alpha-emitting radium and actinium radionuclides. Nucl. Med. Biol. 2004, 31:441-449.
113. Freedman M., Chang E.H., Zhou Q., Pirollo K.F. Nanodelivery of MRI contrast agent enhances sensitivity of detection of lung cancer metastases. Acad. Radiol. 2009, 16:627-637.
114. Miyata S., Kawabata S., Hiramatsu R., Doi A., Ikeda N., Yamashita T., Kuroiwa T., Kasaoka S., Maruyama K., Miyatake S. computed tomography imaging of transferrin targeting liposomes encapsulating both boron and iodine contrast agents by convection-enhanced delivery to F98 rat glioma for boron neutron capture therapy. Neurosurgery 2011, 68:1380-1387.
115. Beuttler J., Rothdiener M., Mueller D., Frejd F.Y., Kontermann R.E. Targeting of epidermal growth factor receptor (EGFR)-expressing tumor cells with sterically stabilized affibody liposomes (SAL). Bioconjug. Chem. 2009, 20:1201-1208.
116. Fondell A., Edwards K., Ickenstein L.M., Sjoberg S., Carlsson J., Gedda L. Nuclisome: A novel concept for radionuclide therapy using targeting liposomes. Eur. J. Nucl. Med. Mol. Imaging 2010, 37:114-123.
117. Gao J., Liu W., Xia Y., Li W., Sun J., Chen H., Li B., Zhang D., Qian W., Meng Y., Deng L., Wang H., Chen J., Guo Y. The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes. Biomaterials 2011, 32:3459-3470.
118. Mamot C., Drummond D., Noble C., Kallab V., Guo Z., Hong K., Kirpotin D., Park J. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res. 2005, 65:11631-11638.
119. Portnoy E., Lecht S., Lazarovici P., Danino D., Magdassi S. Cetuximab-labeled liposomes containing near-infrared probe for in vivo imaging. Nanomed. Nanotechnol. 2011, 7:480-488.
120. Zhang J., Jin W., Wang X., Wang J., Zhang X., Zhang Q. A novel octreotide modified lipid vesicle improved the anticancer efficacy of doxorubicin in somatostatin receptor 2 positive tumor models. Mol. Pharm. 2010, 7:1159-1168.
121. 64Cu-TATE-liposomes in a human neuroendocrine carcinoma mouse model. J. Controlled Release 2012, 160:254-263.
122. Kondo M., Asai T., Katanasaka Y., Sadzuka Y., Tsukada H., Ogino K., Taki T., Baba K., Oku N. Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase. Int. J. Cancer 2004, 108:301-306.
123. Medina O., Kairemo K., Valtanen H., Kangasniemi A., Kaukinen S., Ahonen I., Permi P., Annila A., Sneck M., Holopainen J., Karonen S., Kinnunen P., Koivunen E. Radionuclide imaging of tumor xenografts in mice using a gelatinase-targeting peptide. Anticancer. Res. 2005, 25:33-42.
124. Dagar S., Sekosan M., Lee B., Rubinstein I., Onyuksel H. VIP receptors as molecular targets of breast cancer: Implications for targeted imaging and drug delivery. J. Controlled Release 2001, 74:129-134.
125. Dagar S., Krishnadas A., Rubinstein I., Blend M., Onyuksel H. VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: In vivo studies. J. Controlled Release 2003, 91:123-133.
126. 131I-VIP in rat using gamma camera. Nucl. Med. Biol. 1999, 26:931-936.
127. Iyer A.K., Su Y., Feng J., Lan X., Zhu X., Liu Y., Gao D., Seo Y., VanBrocklin H.F., Broaddus V.C., Liu B., He J. The effect of internalizing human single chain antibody fragment on liposome targeting to epithelioid and sarcomatoid mesothelioma. Biomaterials 2011, 32:2605-2613.
128. Maeda N., Miyazawa S., Shimizu K., Asai T., Yonezawa S., Kitazawa S., Namba Y., Tsukada H., Oku N. Enhancement of anticancer activity in antineovascular therapy is based on the intratumoral distribution of the active targeting carrier for anticancer drugs. Biol. Pharm. Bull. 2006, 29:1936-1940.
129. Turk M., Waters D., Low P. Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma. Cancer Lett. 2004, 213:165-172.
130. Gabizon A., Tzemach D., Gorin J., Mak L., Amitay Y., Shmeeda H., Zalipsky S. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models. Cancer Chemother. Pharmacol. 2010, 66:43-52.
131. Gosk S., Moos T., Gottstein C., Bendas G. VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo. Biochim. Biophys. Acta, Biomembr. 2008, 1778:854-863.
132. Pastorino F., Brignole C., Marimpietri D., Cilli M., Gambini C., Ribatti D., Longhi R., Allen T., Corti A., Ponzoni M. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res. 2003, 63:7400-7409.
133. Torchilin V.P. Targeted pharmaceutical nanocarriers for cancer therapy and Imaging. AAPS J. 2007, 9:E128-E147.
134. Phillips W.T., Goins B. Targeted delivery of imaging agents by liposomes. Handbook of targeted delivery of imaging agents 1995, 149-173. CRC Press, Boca Raton, FL. V.P. Torchilin (Ed.).
135. Ogiharaumeda I., Sasaki T., Toyama H., Oda K., Senda M., Nishigori H. Rapid tumor imaging by active background reduction using biotin-bearing liposomes and avidin. Cancer Res. 1994, 54:463-467.
136. Stabin M.G., Sparks R.B., Crowe E. OLINDA/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicine. J. Nucl. Med. 2005, 46:1023-1027.
137. Fisher D. Internal dosimetry for systemic radiation therapy. Semin. Radiat. Oncol. 2000, 10:123-132.
138. International commission on radiation protection, ICRP The 2007 recommendations of the international commission on radiological protection. Ann. ICRP 2007, 37:2-4.
139. International commission on radiation protection, ICRP Radiological protection in biomedical research. Ann. ICRP 1992, 22(3).
140. Emfietzoglou D., Kostarelos K., Sgouros G. An analytic dosimetry study for the use of radionuclide-liposome conjugates in internal radiotherapy. J. Nucl. Med. 2001, 42:499-504.
141. Kostarelos K., Emfietzoglou D. Tissue dosimetry of liposome-radionuclide complexes for internal radiotherapy: Toward liposome-targeted therapeutic radiopharmaceuticals. Anticancer. Res. 2000, 20:3339-3345.
142. 188Re-liposome and 5-FU in a CT26-luc lung-metastatic mice model. Nucl. Med. Biol. 2012, 39:35-43.
143. 177Lu-pegylated liposomes conjugates in tumor-bearing mice. Nucl. Instrum. Methods A. 2006, 569:533-537.
144. Food and Drug Administration, U.S.FDA's Guidance PET Drugs - Current good manufacturing practice (cGMP) http://www.fda.gov.
145. Food and Drug Administration, U.S.FDA's Guidance for industry Liposome drug product http://www.fda.gov.
146. Food and Drug Administration, U.S.FDA's Guidance for industry Developing medical imaging drug and biological products. Part 1: Conducting safety assessments 2004, (http://www.fda.gov).
147. 177Lu-DOTATATE: which is a better therapy option?. Eur. J. Nucl. Med. Mol. Imaging 2011, 38:1788-1797.
148. DiMasi J. Risks in new drug development: Approval success rates for investigational drugs. Clin. Pharmacol. Ther. 2001, 69:297-307.
149. Lappin G., Garner R. Big physics, small doses: The use of AMS and PET in human microdosing of development drugs. Nat. Rev. Drug Discov. 2003, 2:233-240.
150. EMEA Position paper on non-clinical safety studies to support clinical trials with a single microdose http://www.ema.europa.eu/ema.
151. Food and Drug Administration, U.S.FDA's Guidance for industry Exploratory IND studies http://www.fda.gov.
152. Garner R., Lappin G. The phase 0 microdosing concept. Br. J. Clin. Pharmacol. 2006, 61:367-370.
153. Aboagye E., Price P., Jones T. In vivo pharmacokinetics and pharmacodynamics in drug development using positron-emission tomography. Drug Discov. Today 2001, 6:293-302.
154. Kummar S., Rubinstein L., Kinders R., Parchment R.E., Gutierrez M.E., Murgo A.J., Ji J., Mroczkowski B., Pickeral O.K., Simpson M., Hollingshead M., Yang S.X., Helman L., Wiltrout R., Collins J., Tomaszewski J.E., Doroshow J.H. Phase 0 clinical trials: Conceptions and misconceptions. Cancer J. 2008, 14:133-137.
155. De Iaco P., Musto A., Orazi L., Zamagni C., Rosati M., Allegri V., Cacciari N., Al-Nahhas A., Rubello D., Venturoli S., Fanti S. FDG-PET/CT in advanced ovarian cancer staging: Value and pitfalls in detecting lesions in different abdominal and pelvic quadrants compared with laparoscopy. Eur. J. Radiol. 2011, 80:E98-E103.
156. Khanna C., London C., Vail D., Mazcko C., Hirschfeld S. Guiding the optimal translation of new cancer treatments from canine to human cancer patients. Clin. Cancer Res. 2009, 15:5671-5677.
157. Paoloni M., Khanna C. Science and society - Translation of new cancer treatments from pet dogs to humans. Nat. Rev. Cancer 2008, 8:147-156.
158. LeRoy B.E., Northrup N. Prostate cancer in dogs: Comparative and clinical aspects. Vet. J. 2009, 180:149-162.
159. Willmann J.K., van Bruggen N., Dinkelborg L.M., Gambhir S.S. Molecular imaging in drug development. Nat. Rev. Drug Discov. 2008, 7:591-607.
160. Turkbey B., Kobayashi H., Ogawa M., Bernardo M., Choyke P.L. Imaging of tumor angiogenesis: Functional or targeted?. Am. J. Roentgenol. 2009, 193:304-313.
161. Fass L. Imaging and cancer: A review. Mol. Oncol. 2008, 2:115-152.
162. Anderson H., Yap J., Miller M., Robbins A., Jones T., Price P. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J. Clin. Oncol. 2003, 21:2823-2830.
163. Ginos J., Cooper A., Dhawan V., Lai J., Strother S., Alcock N., Rottenberg D. [N-13] cisplatin PET to assess pharmacokinetics of intraarterial versus intravenous chemotherapy for malignant brain-tumors. J. Nucl. Med. 1987, 28:1844-1852.
164. 18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma. Cancer Res. 1997, 57:3415-3423.
165. 18F]fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer: Preliminary study. Cancer Biother. Radiopharm. 1996, 11:235-245.
166. Su H., Bodenstein C., Dumont R.A., Seimbille Y., Dubinett S., Phelps M.E., Herschman H., Czernin J., Weber W. Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin. Cancer Res. 2006, 12:5659-5667.
167. Mankoff D., Dunnwald L., Gralow J., Ellis G., Schubert E., Tseng J., Lawton T., Linden H., Livingston R. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J. Nucl. Med. 2003, 44:1806-1814.
168. Hung S., Deng W., Yang W., Liu R., Lee C., Su T., Lin R., Yang D., Chang C., Chen W., Wei H., Gelovani J. Mesenchymal stem cell targeting of microscopic tumors and tumor stroma development monitored by noninvasive in vivo positron emission tomography imaging. Clin. Cancer Res. 2005, 11:7749-7756.
169. Solomon B., Binns D., Roselt P., Weibe L., McArthur G., Cullinane C., Hicks R. Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging. Mol. Cancer Ther. 2005, 4:1417-1422.
170. 18F-ML-10, a PET tracer for apoptosis: First human study. J. Nucl. Med. 2011, 52:720-725.
171. 18F-labeled RGD peptide: Initial evaluation for imaging brain tumor angiogenesis. Nucl. Med. Biol. 2004, 31:179-189.
172. 18F-Galacto-RGD in cancer patients. J. Nucl. Med. 2005, 46:1333-1341.
173. 3expression in man. Clin. Cancer Res. 2006, 12:3942-3949.
174. 18F-FDG. J. Nucl. Med. 2008, 49:22-29.
175. 18F-AH111585 in breast cancer patients. J. Nucl. Med. 2008, 49:879-886.
176. 64Cu-labeled RGD peptide. Bioconjug. Chem. 2004, 15:41-49.
177. 18F-labeled matrix metalloproteinase-2 inhibitor. Nucl. Med. Biol. 2003, 30:119-125.
178. 11C]methoxyphenyl)sulfonyl]benzylamino]-3-methylbutanamide. Nucl. Med. Biol. 2004, 31:77-85.
179. 121/rGel. J. Nucl. Med. 2007, 48:445-454.
180. Cai W., Chen K., Mohamedali K.A., Cao Q., Gambhir S.S., Rosenblum M.G., Chen X. PET of vascular endothelial growth factor receptor expression. J. Nucl. Med. 2006, 47:2048-2056.
181. Kayani I., Bomanji J.B., Groves A., Conway G., Gacinovic S., Win T., Dickson J., Caplin M., Ell P.J. Functional Imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1, Tyr3-octreotate) and 18F-FDG. Cancer 2008, 112:2447-2455.
182. Dijkers E.C., Munnink T.H.O., Kosterink J.G., Brouwers A.H., Jager P.L., de Jong J.R., van Dongen G.A., Schroder C.P., Lub-de Hooge M.N., de Vries E.G. Biodistribution of Zr-89-trastuzumab and PET Imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin. Pharmacol. Ther. 2010, 87:586-592.
183. 68Ga-labeled Annexin A5 as a PET imaging agent for apoptosis. Nucl. Med. Biol. 2011, 38:381-392.
184. Jayson G., Zweit J., Jackson A., Mulatero C., Julyan P., Ranson M., Broughton L., Wagstaff J., Hakannson L., Groenewegen G., Bailey J., Smith N., Hastings D., Lawrance J., Haroon H., Ward T., McGown A., Tang M., Levitt D., Marreaud S., Lehmann F., Herold M., Zwierzina H. European Org Res treatment Canc Bi, molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: Implications for trial design of antiangiogenic antibodies. J. Natl. Cancer Inst. 2002, 94:1484-1493.
185. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., Martinez P., Matthews N., Stewart A., Tarpey P., Varela I., Phillimore B., Begum S., McDonald N.Q., Butler A., Jones D., Raine K., Latimer C., Santos C.R., Nohadani M., Eklund A.C., Spencer-Dene B., Clark G., Pickering L., Stamp G., Gore M., Szallasi Z., Downward J., Futreal P.A., Swanton C. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 2012, 366:883-892.
186. Diamandis M., White N.M.A., Yousef G.M. Personalized medicine: Marking a new epoch in cancer patient management. Mol. Cancer Res. 2010, 8:1175-1187.
187. Gedda L., Fondell A., Lundqvist H., Park J.W., Edwards K. Experimental radionuclide therapy of HER2-expressing xenografts using two-step targeting nuclisome particles. J. Nucl. Med. 2012, 53:480-487.
188. Madhankumar A.B., Slagle-Webb B., Wang X., Yang Q.X., Antonetti D.A., Miller P.A., Sheehan J.M., Connor J.R. Efficacy of interleukin-13 receptor-targeted liposomal doxorubicin in the intracranial brain tumor model. Mol. Cancer Ther. 2009, 8:648-654.
189. 1-expressing MDA-MB-231 breast cancer cells. Langmuir 2012, 28:4729-4736.
190. 3 and galectin-1 improves the specificity of paramagnetic/fluorescent liposomes to tumor endothelium in vivo. J. Controlled Release 2012, 158:207-214.
191. Kobayashi T., Ishida T., Okada Y., Ise S., Harashima H., Kiwada H. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells. Int. J. Pharm. 2007, 329:94-102.
192. 4 linkers. Eur. J. Nucl. Med. Mol. Imaging 2009, 36:1296-1307.
193. Temming K., Schiffelers R., Molema G., Kok R. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist. Updates 2005, 8:381-402.
194. Dunne M., Zheng J., Rosenblat J., Jaffray D.A., Allen C. APN/CD13-targeting as a strategy to alter the tumor accumulation of liposomes. J. Controlled Release 2011, 154:298-305.
195. Gao Y., Liu X., Li X. Research progress on siRNA delivery with nonviral carriers. Int. J. Nanomedicine 2011, 6:1017-1025.
196. Weis S.M., Cheresh D.A. Tumor angiogenesis: Molecular pathways and therapeutic targets. Nat. Med. 2011, 17:1359-1370.
197. Mulder W.J.M., van der Schaft D.W.J., Hautvast P.A.I., Strijkers G.J., Koning G.A., Storm G., Mayo K.H., Griffioen A.W., Nicolay K. Early in vivo assessment of angiostatic therapy efficacy by molecular MRI. FASEB J. 2007, 21:378-383.
198. Low P.S., Henne W.A., Doorneweerd D.D. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc. Chem. Res. 2008, 41:120-129.